Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Cervical Carcinoma. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- India
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer (STIRR Cervix Study)
Overview
Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression. Thus the investigators hypothesize that pelvic and/or para-aortic radiotherapy for cervical cancer affects local tumor immunity as well as systemic immune response that may be instrumental for long term cancer cure. The goal of this observational study is to understand the effect of various radiotherapy dose per fraction, total dose and field volumes of radiation on systemic and tumor immune response in cervical cancer. The outcome of the study would be useful in improving the quality of radiation treatment and in reducing disease recurrence and improving survival in patients with cervical cancer.
Detailed description
This study will be performed using blood and tumor material at different time points and available information from blood tests that have been performed prior to initiating chemoradiation in the institution. The proposed sample size is 110 is a convenience based sampling that is based on estimate of people participating in the study during their radiotherapy course. Participants will be allotted in the cohort as per their radiation treatment plan. Collection of blood and tumor tissue material from participants will happen at different time points. These time points will be decided as per the cohort in whom the patient is. The study intends to investigate immunohistochemical (IHC) expression of PD-L1 on baseline and post-treatment tumor biopsy. Furthermore, the study will also investigate expression of immune cells through flow cytometry - fluorescence-activated cell sorter (FACS) at baseline and after RT on blood and tumor tissue sample. The study also intends to capture radiotherapy information - PTV Dose, HRCTV, Mean liver, spleen, Ileocecal junction dose, TRAK values. Using Analysis of Variance (ANOVA) test, all these parameters will be analyzed against their time points in the individual cohorts and also with other cohorts to provide us a better understanding of how pelvic radiotherapy affects our immune system. Furthermore, the investigators will also use Bonferroni correction test to account for multiple statistical comparison. Most of the research studies in cervical cancer that have been published till date do not utilize various aspects of radiotherapy like dose, dose per fraction, field volumes and techniques. This study will represent the first large cohort focusing on all the above mentioned aspects in cervical cancer patients.
Primary outcome measures
- To investigate the systemic immune response in patients undergoing radiotherapy for cervical cancer. [Time frame: 3 years]
- To study the multi-time point interaction between radiotherapy for cervical cancer and impact on tumor infiltrating immune cells and PD-L1 expression. [Time frame: 3 years]
Secondary outcome measures (1)
- To study 3-year disease free survival as a function of baseline and post radiotherapy immune cell composition. [Time frame: 3 years from last date of treatment and/or to date of reccurrence/relapse]
Eligibility criteria
Inclusion criteria
- Common Inclusion Criteria:
- Age 18 years and above.
- Ability to tolerate full course of pelvic radiotherapy+/- chemotherapy +/- brachytherapy.
- Ability to understand and willingness to sign an informed consent document.
- Should be willing to undergo extra biopsies and blood samples collection for translational research study.
Cohort A:
- Patients diagnosed with LACC Stage IB2 - IIIC1, as per FIGO 2018 Classification for Radical Cohort.
- Stage IIIB-IVA where palliative RT is indicated for palliative cohort.
- No previous irradiation to the pelvis or chemo therapy.
Cohort B:
- Patients diagnosed with LACC Stage IIIC2, as per FIGO 2018 Classification.
- No previous irradiation to the pelvis or chemotherapy.
Cohort C:
- Patients diagnosed with gynecological cancer and presenting with need of infield radiation.
- Planned for reirradiation.
Exclusion criteria
- Severe medical condition impairing complete treatment delivery.
- Patients with immunocompromised states or active infection.
- Patients on immunosuppressive drugs for other medical conditions.
- Patients who will receive immune checkpoint inhibition (ICI) therapy.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
India · 1 center
- Tata Memorial Centre — Mumbai
Identifiers
NCT: NCT06804135 · TMH IEC1 No 4591